Acasti Pharma Stock (NASDAQ:ACST)

Ownership Financials Chart

Previous Close

$3.60

52W Range

$1.98 - $3.60

50D Avg

$2.92

200D Avg

$2.95

Market Cap

$34.17M

Avg Vol (3M)

$31.70K

Beta

1.52

Div Yield

-

ACST Company Profile

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

32

IPO Date

Feb 07, 2012

Website

ACST Performance

ACST Financial Summary

	Mar 24	Mar 23	Mar 22
Revenue	-	-	-
Operating Income	$-23.71M	$15.72M	$-15.59M
Net Income	$-14.69M	$-42.43M	$-9.82M
EBITDA	$-23.71M	$15.85M	$-19.99M
Basic EPS	$-1.54	$-5.71	$-1.60
Diluted EPS	$-1.54	$-5.71	$-1.60

Fiscal year ends in Mar 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 23Feb 14, 23 | 3:53 PM

Q2 23Nov 14, 22 | 11:23 PM

Q1 23Aug 11, 22 | 3:55 PM

Peer Comparison

Ticker	Company
GOVX	GeoVax Labs, Inc.
ARDS	Aridis Pharmaceuticals, Inc.
PULM	Pulmatrix, Inc.
ABVC	ABVC BioPharma, Inc.
BPTH	Bio-Path Holdings, Inc.
ADTX	Aditxt, Inc.
TNXP	Tonix Pharmaceuticals Holding Corp.
DFFN	CervoMed Inc.
AKTX	Akari Therapeutics, Plc
JAGX	Jaguar Health, Inc.
MBRX	Moleculin Biotech, Inc.
ONTX	Traws Pharma, Inc.
CBIO	Gyre Therapeutics, Inc.
OCGN	Ocugen, Inc.